The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications
Abstract
Background: Monoclonal antibodies that target calcitonin gene-related peptide or the canonical calcitonin gene-related peptide receptor have emerged as effective and well tolerated for the preventive treatment of migraine. These large molecules appear ideally suited for migraine prevention. They have an extended biological half-life, are administered either monthly or quarterly either by subcutaneous injection or intravenous infusion, require minimal or no dose-titration and have the potential for a rapid onset of effect compared to conventional oral preventive drugs. There is high selectivity and they target an important mediator in the pathogenesis of migraine. Investigation: Phase II and pivotal phase III studies have all yielded positive results with a favorable adverse event profile. No serious treatment-related adverse outcomes have thus far been reported in controlled or long-term open-label extension studies. This tolerability profile promises to improve adherence and, possibly, long-term outcomes. Conclusions: Calcitonin gene-related peptide monoclonal antibodies are effective and well tolerated for the preventive treatment of migraine. They have distinct advantages over currently available oral preventive drugs. While treatment-related serious adverse events have not been observed in open-label extension studies, long-term outcomes and safety will require broad exposure in heterogeneous patient populations in clinical practice. In addition, their safety in women, especially during pregnancy, will require longitudinal surveillance. Given the overlapping mechanism(s), the effectiveness of existing (triptans) and emerging (calcitonin gene-related peptide receptor antagonists) acute therapies in those using a calcitonin gene-related peptide mAb will require further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An IgG‐transporting Fc receptor expressed in the syncytiotrophoblast of human placenta
Simister, N. E., Story, C. M., Chen, H., & Hunt, J. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260718 · Cited by 332
Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies
Meng, I. D., Dodick, D., Ossipov, M. H., & Porreca, F. (2011) · Cephalalgia · doi:10.1177/0333102411402367 · Cited by 70
Self-citation
Cited by
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Buse, D. C., Yugrakh, M. S., Lee, L. K., Bell, J., Cohen, J. M., & Lipton, R. B. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.20100 · Cited by 50
Metadata
- Authors
- Dodick, D. W.
- Venue
- Cephalalgia
- Publisher
- SAGE Publications
- Published
- 2019-01-19
- Volume
- 39
- Issue
- 3
- Pages
- 445-458
- ISSN
- 0333-1024 (ISSN-L)
- 1468-2982
- OpenAlex
- W2910809224
- Cited by
- 180
- References
- 2
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. https://app.cochat.ai/papers/10.1177/0333102418821662
- The paper
- Dodick, D. W. (2019). CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia. https://doi.org/10.1177/0333102418821662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.